Author

E. Van Dis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:mouse· 4 Assay:bulk RNA-seq· 3 Research Focus:host-pathogen & immune response· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:proteomics· 1

Frequent Co-Authors

S. A. Stanley· 3 shared S. Stanley· 3 shared X. Nguyenla· 3 shared C. Dugast-Darzacq· 2 shared D. M. Fines· 2 shared E. Wehri· 2 shared G. R. Golovkine· 2 shared H. M. Morrison· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

S. A. Stanley

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Tuberculosis susceptibility in genetically diverse mice reveals functional diversity of neutrophils

M. M. Ravesloot-Chavez, E. Van Dis, D. Fox, A. Anaya-Sanchez, S. Espich, X. H. Nguyenla, S. L. Rawal, H. Samani, M. A. Ballinger, H. Thomas, D. I. Kotov, R. Vance, M. Nachman, S. Stanley

The paper identifies a novel neutrophil signature associated with poor tuberculosis control in genetically diverse mice.

bioRxiv · Jun 29, 2023Immunology

Deficiency in Galectin-3, -8, and -9 impairs immunity to chronic Mycobacterium tuberculosis infection but not acute infection with multiple intracellular pathogens

H. M. Morrison, J. Craft, R. Rivera-Lugo, J. R. Johnson, G. R. Golovkine, C. E. Dodd, E. Van Dis, W. L. Beatty, S. R. Margolis, T. Repasy, I. Shaker, A. Y. Lee, R. E. Vance, S. A. Stanley, N. J. Krogan, , J. S. Cox

bioRxiv · Dec 29, 2022 · PreprintImmunology

IFN-γ-independent control of M. tuberculosis requires CD4 T cell-derived GM-CSF and activation of HIF-1α

E. Van Dis, H. M. Morrison, D. M. Fines, J. P. Babirye, L. H. McCann, S. Rawal, J. S. Cox, S. A. Stanley

This study identifies GM-CSF and HIF-1 activation as IFN-γ-independent mechanisms by which CD4 T cells control M. tuberculosis infection.

bioRxiv · Dec 16, 2021Immunology

Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2

S. B. Biering, E. Van Dis, E. Wehri, L. H. Yamashiro, X. Nguyenla, C. Dugast-Darzacq, T. G. Graham, J. R. Stroumza, G. R. Golovkine, A. W. Roberts, D. M. Fines, J. N. Spradlin, C. C. Ward, T. Bajaj, D. Dovala, , S. A. Stanley

This study screens FDA-approved compounds for antiviral activity against SARS-CoV-2 and identifies 13 effective compounds, including seven new candidates and one synergistic combination with remdesivir.

bioRxiv · Dec 30, 2020Microbiology

Mucosal vaccination with cyclic-di-nucleotide adjuvants induces effective T cell homing and IL-17 dependent protection against M. tuberculosis infection

R. M. Jong, E. Van Dis, X. Nguyenla, A. Baltodano, G. Pastenkos, C. Xu, N. Yosef, S. McWhirter, S. Stanley

This study shows mucosal vaccination with CDN adjuvants induces T cells that home to lungs and provide IL-17-dependent protection against M. tuberculosis.

bioRxiv · Nov 25, 2020 · PreprintImmunology

Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells

X. Nguyenla, E. Wehri, E. Van Dis, S. Biering, L. H. Yamashiro, J. Stroumza, C. Dugast-Darzacq, T. Graham, S. Stanley, J. Schaletzky

This study identifies 20 approved drugs that synergize with remdesivir to inhibit SARS-CoV-2 replication in human lung cells, with HCV NS5A inhibitors showing the strongest effects.

bioRxiv · Sep 18, 2020Microbiology